Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/08 → 8/31/09 |
Funding
- Wyeth Pharmaceuticals Inc: $1,502.00
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22- Positive, Follicular B-Cell
- Fleischman, Roger (PI)